

Rosario Vasta

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2583013/publications.pdf>

Version: 2024-02-01

144
papers

3,533
citations

172386

29
h-index

175177

52
g-index

146
all docs

146
docs citations

146
times ranked

5090
citing authors

#	ARTICLE	IF	CITATIONS
1	Amyotrophic lateral sclerosis caregiver burden and patients' quality of life during COVID-19 pandemic. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2022, 23, 146-148.	1.1	15
2	What is amyotrophic lateral sclerosis prevalence?. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2022, 23, 203-208.	1.1	8
3	Burden of Parkinson's disease in Sicily: a health administrative database study. <i>Neurological Sciences</i> , 2022, 43, 1043-1046.	0.9	1
4	Tailoring patients' enrollment in ALS clinical trials: the effect of disease duration and vital capacity cutoffs. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2022, 23, 108-115.	1.1	1
5	Parkinsonism and cerebrospinal fluid disorders. <i>Journal of the Neurological Sciences</i> , 2022, 433, 120019.	0.3	6
6	Opinion, knowledge, and clinical experience with functional neurological disorders among Italian neurologists: results from an online survey. <i>Journal of Neurology</i> , 2022, 269, 2549-2559.	1.8	8
7	Pure sensitive chronic inflammatory axonal polyneuropathy following Pfizer COVID-19 vaccine. <i>Neurological Sciences</i> , 2022, 43, 1431-1433.	0.9	5
8	Spinal needle and post-dural puncture headache. <i>Neurological Sciences</i> , 2022, 43, 1467-1468.	0.9	1
9	Incidence and spatial distribution of adult-onset primary malignant and other central nervous system tumors in Southern Sardinia, Italy. <i>Neurological Sciences</i> , 2022, 43, 419-425.	0.9	0
10	Unraveling the complex interplay between genes, environment, and climate in ALS. <i>EBioMedicine</i> , 2022, 75, 103795.	2.7	32
11	Amyotrophic lateral sclerosis with SOD1 mutations shows distinct brain metabolic changes. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 2242-2250.	3.3	9
12	Executive functioning and serum lipid fractions in Parkinson's disease: a possible sex-effect: the PACOS study. <i>Journal of Neural Transmission</i> , 2022, 129, 287-293.	1.4	7
13	Causal associations of genetic factors with clinical progression in amyotrophic lateral sclerosis. <i>Computer Methods and Programs in Biomedicine</i> , 2022, 216, 106681.	2.6	3
14	Incidence of amyotrophic lateral sclerosis in Sardinia, Italy: age-sex interaction and spatial-temporal variability. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2022, 23, 585-591.	1.1	7
15	Obsessive-compulsive personality disorder in rapid eye movement sleep behavior disorder. <i>Scientific Reports</i> , 2022, 12, 2401.	1.6	0
16	Brain ¹⁸ F-fluorodeoxyglucose-positron emission tomography changes in amyotrophic lateral sclerosis with TARDBP mutations. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 1021-1023.	0.9	4
17	Predicting functional impairment trajectories in amyotrophic lateral sclerosis: a probabilistic, multifactorial model of disease progression. <i>Journal of Neurology</i> , 2022, 269, 3858-3878.	1.8	7
18	Identifying and predicting amyotrophic lateral sclerosis clinical subgroups: a population-based machine-learning study. <i>The Lancet Digital Health</i> , 2022, 4, e359-e369.	5.9	19

#	ARTICLE	IF	CITATIONS
19	Validation of the Italian version of the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS) administered to patients and their caregivers. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2022, 23, 424-429.	1.1	2
20	Relationship between risk and protective factors and clinical features of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2022, 98, 80-85.	1.1	12
21	Social cognition deficits in amyotrophic lateral sclerosis: A pilot cross-sectional population-based study. <i>European Journal of Neurology</i> , 2022, 29, 2211-2219.	1.7	8
22	Parkinsonism in idiopathic normal pressure hydrocephalus: is it time for defining a clinical tetrad?. <i>Neurological Sciences</i> , 2022, 43, 5201-5205.	0.9	6
23	Respiratory support in a population-based ALS cohort: demographic, timing and survival determinants. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 1024-1026.	0.9	8
24	An update on idiopathic intracranial hypertension in adults: a look at pathophysiology, diagnostic approach and management. <i>Journal of Neurology</i> , 2021, 268, 3249-3268.	1.8	36
25	Differential Neuropsychological Profile of Patients With Amyotrophic Lateral Sclerosis With and Without C9orf72 Mutation. <i>Neurology</i> , 2021, 96, e141-e152.	1.5	17
26	Brain metabolic changes across King's stages in amyotrophic lateral sclerosis: a 18F-2-fluoro-2-deoxy-d-glucose-positron emission tomography study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1124-1133.	3.3	10
27	Brain metabolic correlates of apathy in amyotrophic lateral sclerosis: An 18F-FDG-positron emission tomography stud. <i>European Journal of Neurology</i> , 2021, 28, 745-753.	1.7	10
28	Metabolic brain changes across different levels of cognitive impairment in ALS: a ¹⁸ F-FDG-PET study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 357-363.	0.9	14
29	Neck flexor weakness at diagnosis predicts respiratory impairment in amyotrophic lateral sclerosis. <i>European Journal of Neurology</i> , 2021, 28, 1181-1187.	1.7	4
30	Mutational Analysis of Known ALS Genes in an Italian Population-Based Cohort. <i>Neurology</i> , 2021, 96, e600-e609.	1.5	23
31	The interplay among education, brain metabolism, and cognitive impairment suggests a role of cognitive reserve in Amyotrophic Lateral Sclerosis. <i>Neurobiology of Aging</i> , 2021, 98, 205-213.	1.5	15
32	Validation of the Italian version of self-administered ALSFRS-R scale. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2021, 22, 151-153.	1.1	9
33	Vascular risk factors, white matter lesions and cognitive impairment in Parkinson's disease: the PACOS longitudinal study. <i>Journal of Neurology</i> , 2021, 268, 549-558.	1.8	28
34	Telemedicine for patients with amyotrophic lateral sclerosis during COVID-19 pandemic: an Italian ALS referral center experience. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2021, 22, 308-311.	1.1	27
35	Prevalence of idiopathic REM behavior disorder: a systematic review and meta-analysis. <i>Sleep</i> , 2021, 44, .	0.6	26
36	Do ecological factors influence the clinical presentation of amyotrophic lateral sclerosis?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 1017-1019.	0.9	4

#	ARTICLE	IF	CITATIONS
37	The links between diabetes mellitus and amyotrophic lateral sclerosis. <i>Neurological Sciences</i> , 2021, 42, 1377-1387.	0.9	18
38	Usefulness of a smartphone application for the diagnosis of epilepsy: Validation study in high-income and rural low-income countries. <i>Epilepsy and Behavior</i> , 2021, 115, 107680.	0.9	7
39	Structural MRI substrate of long-duration response to levodopa in Parkinson's disease: an exploratory study. <i>Journal of Neurology</i> , 2021, 268, 4258-4264.	1.8	4
40	A novel splice site FUS mutation in a familial ALS case: effects on protein expression. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2021, , 1-9.	1.1	2
41	Prevalence of isolated RBD in the city of Catania, Italy: a population-based study. <i>Journal of Clinical Sleep Medicine</i> , 2021, 17, 2241-2248.	1.4	11
42	The impact of COVID-19 pandemic on frail health systems of low- and middle-income countries: The case of epilepsy in the rural areas of the Bolivian Chaco. <i>Epilepsy and Behavior</i> , 2021, 118, 107917.	0.9	4
43	Retinal thickness and microvascular pathway in Idiopathic Rapid eye movement sleep behaviour disorder and Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2021, 88, 40-45.	1.1	16
44	Arterial blood gas analysis: base excess and carbonate are predictive of noninvasive ventilation adaptation and survival in amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2021, 22, 33-39.	1.1	8
45	The heterozygous deletion c.1509_1510delAG in exon 14 of FUS causes an aggressive childhood-onset ALS with cognitive impairment. <i>Neurobiology of Aging</i> , 2021, 103, 130.e1-130.e7.	1.5	7
46	Does an association between cigarette smoking and Parkinson's Disease-related psychosis exist? Insights from a large non-demented cohort. <i>Journal of the Neurological Sciences</i> , 2021, 427, 117509.	0.3	1
47	Can amyotrophic lateral sclerosis progression really pause? A cohort study using the medical research council scale. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2021, , 1-7.	1.1	1
48	Neuroticism and Risk of Parkinson's Disease: A Meta-Analysis. <i>Movement Disorders</i> , 2021, 36, 2215-2215.	2.2	0
49	GBA variants influence cognitive status in amyotrophic lateral sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, , jnnp-2021-327426.	0.9	3
50	Impulsivity traits in eyelid myoclonia with absences. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2021, 91, 393-396.	0.9	0
51	Neuroanatomical changes in early Parkinson's disease with mild cognitive impairment: a VBM study; the Parkinson's Disease Cognitive Impairment Study (PaCoS). <i>Neurological Sciences</i> , 2021, 42, 3723-3731.	0.9	18
52	Cognitive impairment and levodopa induced dyskinesia in Parkinson's disease: a longitudinal study from the PACOS cohort. <i>Scientific Reports</i> , 2021, 11, 867.	1.6	9
53	Use of antipsychotics and long-term risk of parkinsonism. <i>Neurological Sciences</i> , 2021, , 1.	0.9	4
54	Influence of Drugs on Mild Cognitive Impairment in Parkinson's Disease: Evidence from the PACOS Study. <i>Current Neuropharmacology</i> , 2021, 20, .	1.4	1

#	ARTICLE	IF	CITATIONS
55	Lack of association between <i>Toxocara canis</i> and multiple sclerosis: A population-based case-control study. <i>Multiple Sclerosis Journal</i> , 2020, 26, 258-259.	1.4	3
56	Incidence of multiple sclerosis in the province of Catania. A geo-epidemiological study. <i>Environmental Research</i> , 2020, 182, 109022.	3.7	10
57	Regional spreading of symptoms at diagnosis as a prognostic marker in amyotrophic lateral sclerosis: a population-based study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 291-297.	0.9	18
58	Retinal Thickness and Microvascular Pattern in Early Parkinson's Disease. <i>Frontiers in Neurology</i> , 2020, 11, 533375.	1.1	26
59	Transcranial random noise stimulation over the primary motor cortex in PD-MCI patients: a crossover, randomized, sham-controlled study. <i>Journal of Neural Transmission</i> , 2020, 127, 1589-1597.	1.4	11
60	The Characteristics of Cognitive Impairment in ALS Patients Depend on the Lateralization of Motor Damage. <i>Brain Sciences</i> , 2020, 10, 650.	1.1	8
61	Nabiximols discontinuation rate in a large population of patients with multiple sclerosis: a 18-month multicentre study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 914-920.	0.9	5
62	Lifetime sport practice and brain metabolism in Amyotrophic Lateral Sclerosis. <i>NeuroImage: Clinical</i> , 2020, 27, 102312.	1.4	7
63	Parasomnias, sleep-related movement disorders and physiological sleep variants in focal epilepsy: A polysomnographic study. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2020, 81, 84-90.	0.9	9
64	Clinical and Electrophysiological Hints to TMS in De Novo Patients with Parkinson's Disease and Progressive Supranuclear Palsy. <i>Journal of Personalized Medicine</i> , 2020, 10, 274.	1.1	24
65	Changes in Motor, Cognitive, and Behavioral Symptoms in Parkinson's Disease and Mild Cognitive Impairment During the COVID-19 Lockdown. <i>Frontiers in Psychiatry</i> , 2020, 11, 590134.	1.3	46
66	<i>Toxoplasma gondii</i> and multiple sclerosis: a population-based case-control study. <i>Scientific Reports</i> , 2020, 10, 18855.	1.6	12
67	Asymmetry index of Blink Reflex Recovery Cycle differentiates Parkinson's disease from atypical Parkinsonian syndromes. <i>Journal of Neurology</i> , 2020, 267, 1859-1863.	1.8	6
68	Administration of subcutaneous interferon beta 1a in the evening: data from RELIEF study. <i>Journal of Neurology</i> , 2020, 267, 1812-1823.	1.8	3
69	The role of arterial blood gas analysis (ABG) in amyotrophic lateral sclerosis respiratory monitoring. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 999-1000.	0.9	13
70	CSF neurotoxic metals/metalloids levels in amyotrophic lateral sclerosis patients: comparison between bulbar and spinal onset. <i>Environmental Research</i> , 2020, 188, 109820.	3.7	17
71	Prognostic role of slow vital capacity in amyotrophic lateral sclerosis. <i>Journal of Neurology</i> , 2020, 267, 1615-1621.	1.8	18
72	ALS phenotype is influenced by age, sex, and genetics. <i>Neurology</i> , 2020, 94, e802-e810.	1.5	99

#	ARTICLE	IF	CITATIONS
73	Plateaus in amyotrophic lateral sclerosis progression: results from a population-based cohort. <i>European Journal of Neurology</i> , 2020, 27, 1397-1404.	1.7	11
74	A familial amyotrophic lateral sclerosis pedigree discordant for a novel p.Glu46Asp heterozygous OPTN variant and the p.Ala5Val heterozygous SOD1 missense mutation. <i>Journal of Clinical Neuroscience</i> , 2020, 75, 223-225.	0.8	3
75	Comic book-based educational program on epilepsy for high-school students: Results from a pilot study in the Gran Chaco region, Bolivia. <i>Epilepsy and Behavior</i> , 2020, 107, 107076.	0.9	14
76	Comorbidity of Cervical Spondylogenic Myelopathy and Amyotrophic Lateral Sclerosis: When Electromyography Makes the Difference in Diagnosis. <i>European Neurology</i> , 2020, 83, 626-629.	0.6	1
77	Seroprevalence of <i>Toxocara canis</i> in the city of Catania, Italy.. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2019, 11, e2019031.	0.5	9
78	Patient perspectives on the acceptability of mHealth technology for remote measurement and management of epilepsy: A qualitative analysis. <i>Epilepsy and Behavior</i> , 2019, 97, 123-129.	0.9	36
79	Basal ganglia calcifications (Fahr's syndrome): related conditions and clinical features. <i>Neurological Sciences</i> , 2019, 40, 2251-2263.	0.9	73
80	Cardiovascular autonomic function and MCI in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 69, 55-58.	1.1	11
81	Amyotrophic lateral sclerosis spatial epidemiology in the Mount Etna region, Italy. <i>European Journal of Neurology</i> , 2019, 26, e90-e91.	1.7	7
82	Febrile infection-related epilepsy syndrome (FIRES) in an adult patient: an early neuroradiological finding. <i>Neurological Sciences</i> , 2019, 40, 2407-2410.	0.9	4
83	A Dynamic Bayesian Network model for the simulation of Amyotrophic Lateral Sclerosis progression. <i>BMC Bioinformatics</i> , 2019, 20, 118.	1.2	20
84	Mild Behavioral Impairment in Parkinson's Disease: Data from the Parkinson's Disease Cognitive Impairment Study (PACOS). <i>Journal of Alzheimer's Disease</i> , 2019, 68, 1603-1610.	1.2	12
85	Parkinsonian traits in amyotrophic lateral sclerosis (ALS): a prospective population-based study. <i>Journal of Neurology</i> , 2019, 266, 1633-1642.	1.8	25
86	Accuracy of MDS-UPDRS section IV for detecting motor fluctuations in Parkinson's disease. <i>Neurological Sciences</i> , 2019, 40, 1271-1273.	0.9	5
87	Incidence of Mild Cognitive Impairment and Dementia in Parkinson's Disease: The Parkinson's Disease Cognitive Impairment Study. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 21.	1.7	62
88	Cognitive impairment across ALS clinical stages in a population-based cohort. <i>Neurology</i> , 2019, 93, e984-e994.	1.5	115
89	Knowledge, stigma, and quality of life in epilepsy: Results before and after a community-based epilepsy awareness program in rural Bolivia. <i>Epilepsy and Behavior</i> , 2019, 92, 90-97.	0.9	22
90	Knowledge, attitudes, and practices towards epilepsy among general practitioners in rural Bolivia: Results before and after a training program on epilepsy. <i>Epilepsy and Behavior</i> , 2018, 83, 113-118.	0.9	13

#	ARTICLE	IF	CITATIONS
91	Forehead Tremor: A Clinical Presentation of Myasthenia Gravis?. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 225-226.	0.8	1
92	Spatial epidemiology of amyotrophic lateral sclerosis in Piedmont and Aosta Valley, Italy: a population-based cluster analysis. <i>European Journal of Neurology</i> , 2018, 25, 756-761.	1.7	9
93	Clinical and CN-SFEMG evaluation of neostigmine test in myasthenia gravis. <i>Neurological Sciences</i> , 2018, 39, 341-345.	0.9	7
94	Aging and Parkinson's Disease: Inflammaging, neuroinflammation and biological remodeling as key factors in pathogenesis. <i>Free Radical Biology and Medicine</i> , 2018, 115, 80-91.	1.3	255
95	Treating People With Epilepsy in Rural Low-Income Countries Is Feasible. Observations and Reflections From a "Real Life Experience" After a Long Lasting Intervention in the Rural Chaco. <i>Frontiers in Neurology</i> , 2018, 9, 855.	1.1	6
96	Adult-Onset Sleepwalking Secondary to Hyperthyroidism: Polygraphic Evidence. <i>Journal of Clinical Sleep Medicine</i> , 2018, 14, 285-287.	1.4	10
97	Vascular Parkinsonism: Still Looking for a Diagnosis. <i>Frontiers in Neurology</i> , 2018, 9, 411.	1.1	12
98	Hormetic approaches to the treatment of Parkinson's disease: Perspectives and possibilities. <i>Journal of Neuroscience Research</i> , 2018, 96, 1641-1662.	1.3	75
99	Knowledge and attitudes towards epilepsy among nonmedical health workers in rural Bolivia: Results after a long-term activity in the Chaco region. <i>Epilepsy and Behavior</i> , 2018, 85, 58-63.	0.9	12
100	Cognitive-motor dual-task interference: A systematic review of neural correlates. <i>Neuroscience and Biobehavioral Reviews</i> , 2017, 75, 348-360.	2.9	179
101	Video analysis of epileptic-like motor patterns in REM behaviour disorder: a case series. <i>Neurological Sciences</i> , 2017, 38, 699-701.	0.9	0
102	Electroclinical findings of minor motor events during sleep in temporal lobe epilepsy. <i>Epilepsia</i> , 2017, 58, 1261-1267.	2.6	5
103	Validity of medico-administrative data related to amyotrophic lateral sclerosis in France: A population-based study. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2017, 18, 24-31.	1.1	9
104	Quantitative estimation of motor fluctuations in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2017, 42, 34-39.	1.1	4
105	Gender effect on non-motor symptoms in Parkinson's disease: are men more at risk?. <i>Parkinsonism and Related Disorders</i> , 2017, 35, 69-74.	1.1	53
106	Migraine causes retinal and choroidal structural changes: evaluation with ocular coherence tomography. <i>Journal of Neurology</i> , 2017, 264, 494-502.	1.8	43
107	Dopaminergic and non-dopaminergic gait components assessed by instrumented timed up and go test in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2017, 124, 1539-1546.	1.4	7
108	Vascular parkinsonism or idiopathic NPH? New insights from CSF pressure analysis. <i>Neurological Sciences</i> , 2017, 38, 2209-2212.	0.9	6

#	ARTICLE	IF	CITATIONS
109	Head trauma and Parkinson's disease: results from an Italian case-control study. <i>Neurological Sciences</i> , 2017, 38, 1835-1839.	0.9	11
110	Metals and neurodegenerative diseases. A systematic review. <i>Environmental Research</i> , 2017, 159, 82-94.	3.7	178
111	Magnetic fields exposure from high-voltage power lines and risk of amyotrophic lateral sclerosis in two Italian populations. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2017, 18, 583-589.	1.1	11
112	Switching l-dopa Therapy from Pulsatile to Pulse Administration Reduces Motor Complications in Parkinson's Disease. <i>Clinical Neuropharmacology</i> , 2017, 40, 6-10.	0.2	3
113	Iron and Parkinson's disease: A systematic review and meta-analysis. <i>Molecular Medicine Reports</i> , 2017, 15, 3383-3389.	1.1	27
114	Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study). <i>PLoS ONE</i> , 2017, 12, e0180651.	1.1	24
115	Side effects induced by the acute levodopa challenge in Parkinson's Disease and atypical parkinsonisms. <i>PLoS ONE</i> , 2017, 12, e0172145.	1.1	21
116	Validation of the UPDRS section IV for detection of motor fluctuations in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2016, 27, 98-101.	1.1	13
117	Response to the letter: "Obsessive compulsive personality disorder in Progressive Supranuclear Palsy" by Golimstok. <i>Parkinsonism and Related Disorders</i> , 2016, 33, 144-145.	1.1	0
118	Obsessive compulsive personality disorder in Progressive Supranuclear Palsy, Multiple System Atrophy and Essential Tremor. <i>Parkinsonism and Related Disorders</i> , 2016, 30, 36-39.	1.1	9
119	CSF N-glycan profile reveals sialylation deficiency in a patient with GM2 gangliosidosis presenting as childhood disintegrative disorder. <i>Autism Research</i> , 2016, 9, 423-428.	2.1	25
120	The epidemiology of amyotrophic lateral sclerosis in the Mount Etna region: a possible pathogenic role of volcanogenic metals. <i>European Journal of Neurology</i> , 2016, 23, 964-972.	1.7	34
121	Clinical phenotype and risk of levodopa-induced dyskinesia in Parkinson's disease. <i>Journal of Neurology</i> , 2016, 263, 888-894.	1.8	29
122	Clinical and radiologic rebound after discontinuation of natalizumab therapy in a highly active multiple sclerosis patient was not halted by dimethyl-fumarate: a case report. <i>BMC Neurology</i> , 2015, 15, 252.	0.8	9
123	Coffee consumption and risk of levodopa-induced dyskinesia in Parkinson's disease: The FRAGAMP study. <i>Movement Disorders</i> , 2015, 30, 1854-1856.	2.2	16
124	Increasing the Coding Potential of Genomes Through Alternative Splicing: The Case of PARK2 Gene. <i>Current Genomics</i> , 2014, 15, 203-216.	0.7	32
125	Identification of circulating microRNAs for the differential diagnosis of Parkinson's disease and Multiple System Atrophy. <i>Frontiers in Cellular Neuroscience</i> , 2014, 8, 156.	1.8	150
126	Single Photon Emission Computed Tomography Striatal Asymmetry Index May Predict Dopaminergic Responsiveness in Parkinson Disease. <i>Clinical Neuropharmacology</i> , 2011, 34, 71-73.	0.2	24

#	ARTICLE	IF	CITATIONS
127	Reproductive factors and Parkinson's disease: A multicenter caseâ€“control study. <i>Movement Disorders</i> , 2011, 26, 2563-2566.	2.2	31
128	The FRAGAMP study: environmental and genetic factors in Parkinsonâ€™s disease, methods and clinical features. <i>Neurological Sciences</i> , 2010, 31, 47-52.	0.9	15
129	Voluptuary habits and clinical subtypes of Parkinson's disease: The FRAGAMP caseâ€“control study. <i>Movement Disorders</i> , 2010, 25, 2387-2394.	2.2	35
130	Sex Differences in Clinical and Genetic Determinants of Levodopa Peak-Dose Dyskinesias in Parkinson Disease. <i>Archives of Neurology</i> , 2005, 62, 601.	4.9	195
131	Increased Risk for Alzheimer Disease With the Interaction of MPO and A2M Polymorphisms. <i>Archives of Neurology</i> , 2004, 61, 341.	4.9	45
132	Body Weight Influences Pharmacokinetics of Levodopa in Parkinson's Disease. <i>Clinical Neuropharmacology</i> , 2002, 25, 79-82.	0.2	71
133	Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease. <i>Movement Disorders</i> , 2001, 16, 197-201.	2.2	111
134	Dopamine D2 receptor TaqI A polymorphism and Parkinson's disease. <i>Movement Disorders</i> , 2001, 16, 975-975.	2.2	1
135	Vitamin E deficiency due to chylomicron retention disease in Marinesco-Sjögren syndrome. <i>Annals of Neurology</i> , 2000, 47, 260-264.	2.8	40
136	The dopamine D2 receptor gene is a susceptibility locus for Parkinson's disease. <i>Movement Disorders</i> , 2000, 15, 120-126.	2.2	108
137	Apolipoprotein E Polymorphisms and the Risk of Nonlesional Temporal Lobe Epilepsy. <i>Epilepsia</i> , 1999, 40, 1804-1807.	2.6	36
138	Mild Non-lesional Temporal Lobe Epilepsy: A Common, Unrecognized Disorder with Onset in Adulthood. <i>Canadian Journal of Neurological Sciences</i> , 1998, 25, 282-286.	0.3	55
139	Negative Myoclonic Status Due to Antiepileptic Drug Tapering: Report of Three Cases. <i>Epilepsia</i> , 1997, 38, 819-823.	2.6	18
140	Long-duration response to levodopa influences the pharmacodynamics of short-duration response in Parkinson's disease. <i>Annals of Neurology</i> , 1997, 42, 245-248.	2.8	63
141	Short-term levodopa test assessed by movement time accurately predicts dopaminergic responsiveness in Parkinson's disease. <i>Movement Disorders</i> , 1997, 12, 103-106.	2.2	46
142	Photic-Induced Epileptic Negative Myoclonus: A Case Report. <i>Epilepsia</i> , 1996, 37, 492-494.	2.6	9
143	The subacute levodopa test for evaluating long-duration response in parkinson's disease. <i>Annals of Neurology</i> , 1995, 38, 389-395.	2.8	60
144	Morphometric magnetic resonance imaging corticoâ€“subcortical features in Parkinson's disease with mild cognitive impairment. <i>European Journal of Neurology</i> , 0, , .	1.7	0